Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial.
Ana Maria Copaescu, Sara Vogrin, Fiona James...
https://pubmed.ncbi.nlm.nih.gov/37459086/Actively Recruiting
Led by Deniz Göcebe · Updated on 2025-04-10
100
Participants Needed
2
Research Sites
8 weeks
Total Duration
Researchers are evaluating the safety and negative predictive value of risk-stratified direct drug provocation tests DPT for patients who report penicillin allergies. This study focuses on those identified as low-risk by the PEN-FAST score, an internationally validated tool used to predict true penicillin allergies. The goal is to validate if skipping skin testing before DPT is safe and reliable in these low-risk patients. Participants with a PEN-FAST score of 0-2 points will receive either a one-step or two-step drug provocation test with the suspected penicillin without prior skin testing. They will be monitored for at least four hours for any immediate allergic reactions. Patients will also be asked to report any delayed allergic responses after the test. A comparison group opting for standard care will undergo skin prick and patch testing, allergen-specific IgE measurement, and if negative, the same drug provocation test. Throughout the study, participants will be assessed for allergic reactions and other safety outcomes up to seven days following testing. Researchers will analyze medical history, demographic data, and adverse reactions to compare the performance of direct DPT versus standard testing. The main outcome is the difference in positive findings across skin tests, IgE measurements, and drug provocation tests between the two groups. This study will provide data on the safety and predictive value of skipping skin tests in low-risk penicillin allergy patients.
CONDITIONS
Risk-stratified Testing for Safe Removal of Penicillin Allergy Labels
D
Deniz Göcebe, MD
K
Knut Schäkel, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Deniz Göcebe
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) to assess PEN-FAST score and eligibility
Duration - 1 day
Participants receive either a direct drug provocation test without prior skin testing or standard of care testing including skin prick and patch tests followed by drug provocation if tests are negative.
1 visit (in-person) for drug provocation test and/or skin testing
Duration - 7 days
Participants are monitored for delayed allergic reactions after the drug provocation test and instructed to contact the hospital if symptoms occur.
Contact with hospital as needed for delayed reaction monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Ana Maria Copaescu, Sara Vogrin, Fiona James...
https://pubmed.ncbi.nlm.nih.gov/37459086/Jason A Trubiano, Sara Vogrin, Kyra Y L Chua...
https://pubmed.ncbi.nlm.nih.gov/32176248/Deniz Göcebe
Lead Sponsor